DermaSensor
Company Information
Headquarters
Miami, Florida, USA
Year Founded
2009
Industries
Healthcare, Medical Devices, Dermatology, Primary Care, Health Technology, Clinical Diagnostics
What Is DermaSensor?
DermaSensor is a medical technology company developing an AI-powered skin cancer assessment device for use by healthcare professionals. Its handheld system combines elastic scattering spectroscopy (ESS) with machine learning to analyze suspicious skin lesions at the point of care. The technology evaluates optical characteristics beneath the skin’s surface and provides an objective result that helps clinicians determine whether a lesion should receive further evaluation. DermaSensor sits at the intersection of artificial intelligence, optical sensing, and medical diagnostics.
What Does DermaSensor Do?
DermaSensor provides physicians with a non-invasive method for evaluating suspicious skin lesions during a clinical visit. A clinician places the handheld device against a lesion, where it collects spectral measurements and uses an AI algorithm to analyze characteristics associated with malignancy. The system returns an immediate result of either “Monitor” or “Investigate Further,” helping inform decisions about whether a patient should be referred to a dermatologist.
The device is designed to assist with lesions suggestive of melanoma, basal cell carcinoma, and squamous cell carcinoma. It is an adjunct to clinical assessment rather than a standalone diagnostic or general screening tool.
DermaSensor Technology
DermaSensor combines elastic scattering spectroscopy (ESS) with a proprietary machine learning algorithm. ESS analyzes how light interacts with cellular and subcellular structures beneath the surface of a suspicious lesion. The device emits light into the tissue and measures reflected spectral signals associated with characteristics such as cell density, nucleus size, chromatin, tissue architecture, and melanocyte density.
During an assessment, the device collects multiple spectral recordings from different areas of the lesion. DermaSensor says each recording measures reflectance across 47 wavelengths, creating spectral information that can be evaluated for patterns associated with benign or malignant tissue.
These measurements are processed by a locked, validated AI algorithm trained using more than 20,000 scans from over 4,000 malignant and benign lesions. The analysis produces an immediate “Monitor” or “Investigate Further” result. For an Investigate Further result, the system also provides a spectral score indicating the degree of similarity to malignant lesions.
Why DermaSensor Matters
DermaSensor demonstrates how AI can be combined with optical sensing to provide clinicians with information that cannot be obtained from visual examination alone. Rather than relying on conventional medical images, its technology analyzes spectral characteristics associated with microscopic tissue structures beneath the skin.
The system is particularly relevant to the growing use of AI-assisted point-of-care diagnostics. Its FDA-cleared device gives non-dermatologist physicians an objective tool for evaluating suspicious lesions and deciding when further dermatological assessment may be appropriate. In its pivotal study, the device demonstrated 96% sensitivity across melanoma, basal cell carcinoma, and squamous cell carcinoma.
DermaSensor Products & Platforms
DermaSensor Device
The DermaSensor device is a handheld AI-powered skin lesion assessment system designed for clinical point-of-care use. Physicians place the device directly against a suspicious lesion to collect non-invasive spectral measurements. The measurements are analyzed by the device’s ESS and machine learning technology, producing an immediate result intended to support clinical decision-making.
The device can evaluate lesions suggestive of melanoma, basal cell carcinoma, and squamous cell carcinoma. It also supports secure Wi-Fi connectivity, cloud-based data synchronization, remote device monitoring, and delivery of software updates.
DermaSensor Applications
DermaSensor is primarily used for skin cancer risk assessment in clinical settings. It is designed for physicians who are not dermatologists and can be incorporated into primary-care visits when a suspicious skin lesion has already been identified.
Its applications include evaluating lesions suggestive of melanoma, basal cell carcinoma, and squamous cell carcinoma, supporting decisions about dermatology referrals, and helping healthcare systems prioritize patients requiring additional evaluation. DermaSensor can therefore serve as a bridge between primary care and specialist dermatology services. The device is indicated for patients aged 40 and older and is not intended as a general skin-cancer screening device or as the sole basis for diagnosis.
Latest Companies
Frequently Asked Questions
How does DermaSensor analyze a suspicious skin lesion?
DermaSensor uses elastic scattering spectroscopy to send light into tissue and measure how that light is reflected by cellular and subcellular structures. Its AI algorithm analyzes the resulting spectral information for patterns associated with malignancy.
What types of skin cancer can DermaSensor assess?
The device is indicated to assist in evaluating lesions suggestive of melanoma, basal cell carcinoma, and squamous cell carcinoma—the three common forms of skin cancer addressed by the system.
Is DermaSensor FDA cleared?
Yes. DermaSensor received FDA clearance in 2024 as a Class II medical device for assisting physicians in evaluating lesions suggestive of melanoma, basal cell carcinoma, and squamous cell carcinoma.
Does DermaSensor diagnose skin cancer?
No. DermaSensor is not intended to provide a definitive skin-cancer diagnosis. It provides objective information that physicians can use alongside their clinical assessment when deciding whether a suspicious lesion requires further evaluation or referral to a dermatologist.
Who is DermaSensor designed for?
DermaSensor is designed for physicians who are not dermatologists and other qualified healthcare professionals using it in clinical settings. It is not intended for patients to perform their own skin assessments.
Do You Have an Update for This Company?
Have an update, correction, or additional information about this company? Help us keep the futureTEKnow company database up to date by submitting the latest company information.
Related Companies
Latest Articles
OpenAI Astra for Law Brings GPT-6 Astra Into Legal Research and Law Firm Workflows
OpenAI’s Astra for Law combines GPT-6 Astra with specialized legal search, integrations, and governance controls. The launch shows how frontier AI is moving deeper into professional legal workflows.
Are your AI projects stuck on your own data?
AI projects often stall because business data isn’t consistent or trustworthy. Here’s how to identify data gaps before they become an AI roadblock.
EVAS Intelligence’s RISC-V AI Chips Land 1.5 Billion Yuan Series B to Power Global Expansion
EVAS Intelligence has raised 1.5 billion yuan to mass‑produce its RISC-V Epoch AI chips, deepen its full‑stack platform, and accelerate global expansion, signaling rising investor confidence in alternative AI compute.
Orkes Raises $60M to Orchestrate Enterprise AI Agents in Production
Orkes has raised 60 million dollars to turn its Netflix‑born workflow engine into a control plane for enterprise AI agents. The piece unpacks how its orchestration platform works, why investors are backing it now, and what this means for companies trying to move AI from pilots into production.
Sillage’s AI signal engine raises €1.7M to help enterprise sales teams follow the right buying signals
Paris-based Sillage has raised €1.7 million to launch an AI signal engine that helps enterprise sales teams follow the right buying signals, prioritize high-intent accounts, and improve pipeline efficiency without replacing human-led conversations.
Cloneable’s agentic AI platform targets the infrastructure knowledge gap with $4.6M seed round
Cloneable is launching an agentic AI platform for infrastructure operations that captures institutional knowledge from retiring experts and turns it into scalable agents, targeting energy, utilities, and other asset-heavy sectors. The $4.6M seed-backed startup aims to connect field data capture with back-office execution so founders and operators can modernize infrastructure faster and with fewer bottlenecks.
Ricursive Superintelligence’s $500M bet on self-improving AI raises the stakes in the AGI funding race
Excerpt: Ricursive Superintelligence has raised at least $500 million to build self‑improving AI, with GV and Nvidia backing a four‑month‑old lab at a $4 billion valuation. The deal crystallizes how quickly capital, talent and regulatory scrutiny are converging around autonomous AI research—and what that means for builders trying to compete outside the frontier club.
Bond AI raises US$2M to automate SME accounting in Brazil’s brutal tax maze
Brazilian startup BOND has raised US$2M to automate accounting for SMEs in Brazil’s complex tax system. Combining AI with human accountants, it targets a fragmented market of manual processes, aiming to turn back-office compliance into a faster, more strategic function for founders and operators.
Loop’s AI supply chain platform raises $95M Series C to predict disruptions before they hit
Loop just raised a $95M Series C to expand its AI-native supply chain platform, turning messy logistics data into early disruption warnings and better financial outcomes for global operators and shippers.
London AI startup Lua wants to give every business its own AI workforce with $5.8M seed round
Linkedin X-twitter-square Facebook-square Startups & Business News AI agents are finally moving from demos to the day-to-day stack of real
Factory.ai raises $150M Series C to build fully autonomous software engineering “factories”
Factory has raised a $150M Series C at a $1.5B valuation to scale its autonomous “Droids” platform, betting that enterprises will standardize software engineering around agent‑native missions, governance and cost‑optimized AI infrastructure.
Solidroad’s $25M bet on AI quality assurance for customer support
Solidroad has raised $25 million to bring AI-native quality assurance to every human and AI-powered customer interaction. The new funding will accelerate product development and expansion for support-heavy businesses leaning into automation.
futureTEKnow is focused on identifying and promoting creators, disruptors and innovators, and serving as a vital resource for those interested in the latest advancements in technology.
© 2026 All Rights Reserved.